These are the data of a clinical trial in Schizophrenia (a subset of the dataset
Schizo_Bin, study 1 where the patients were administered 10 mg. of haloperidol or 8 mg. of risperidone). A total of 454 patients were treated by 117 investigators (psychiatrists). Patients' schizophrenia symptoms at baseline and at the end of the study (after 8 weeks) were measured using the PANSS and BPRS.
The variables BPRS_Bin and PANSS_Bin are binary outcomes that indicate whether clinically meaningful change had occurred (1 = a reduction of 20% or higher in the PANSS/BPRS scores at the last measurement compared to baseline; 0 = no such reduction; Leucht et al., 2005; Kay et al., 1988).
data.frame with 454 observations on 5 variables.
The patient ID.
The ID of the investigator (psychiatrist) who treated the patient.
The treatment indicator, coded as -1 = control treatment (10 mg. haloperidol) and 1 = experimental treatment (8 mg. risperidone).
The dichotomized change in the PANSS score (1 = a reduction of 20% or more in the PANSS score, 0=otherwise)
The dichotomized change in the BPRS score (1 = a reduction of 20% or more in the BPRS score, 0=otherwise)
The sichtomized change in the CGI score, coded as 1 = a change of more than 3 points on the original scale (score at the end of the treatment relative to score at the beginning of the treatment), 0 = otherwise.
Kay, S.R., Opler, L.A., & Lindenmayer, J.P. (1988). Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics. Psychiatric Research, 23, 99-110.
Leucht, S., et al. (2005). Clinical implications of Brief Psychiatric Rating Scale scores. The British Journal of Psychiarty, 187, 366-371.